Take a Look! Four New Nonclinical Posters
We are pleased to share with you the four scientific posters that were presented by our nonclinical experts at the annual SOT meeting.
Detection of Plasma Cells and their Precursors in Bone Marrow and Peripheral Blood
Plasma cells are antibody-producing B cells that play a major role in conferring immune protection, but can also contribute to the pathogenesis of autoimmune diseases like multiple sclerosis, and hematologic cancers like multiple myeloma. Read more.
Evaluating Cytokine Data in Non-human Primate Safety Assessment Studies
Cytokines are cell-signaling small proteins classified as either pro-inflammatory or anti-inflammatory. With the increasing number of biologics and immune-modulating drugs being developed, the evaluation of cytokine levels as potential biomarkers in safety assessment studies has become more common. Read more.
Historical Control Reference Values of Cambodian Cynomolgus Macaque Blood Gases
Measuring blood gases can be useful in identifying drug-related respiratory changes like blood changes in the diffusion of gases from the lungs into the bloodstream. For small molecule pharmaceuticals, ICH S7 identifies hemoglobin oxygen saturation (sO2) as a potential part of the core respiratory battery, while other blood gases (e.g., pO2 and pCO2) can be used for supplemental assessment. Read more.
Multiplexed Cytokine Comparison Across Two Species Dosed with the Same Drug
Questions often asked include which assay platform to use (Meso Scale Discovery or Luminex xMAP®), and how relatable are the results between small animals (e.g.,rats) and large animals (e.g., non-human primates)… Our analysis revealed commonalities and differences in cytokine responses across species. Read more.
Book a consult with one of our experts to discuss how we can support your program.
You may also be interested in the following:
- E-book: Preclinical Assessment Planning Guide
- Webpages:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.
Q&A: Setting Up Your Clinical Research for Success, With Dr. Nicole Maciolek
Tying together the phases of your drug development program are the essential research support services that help your drug candidates not only meet their milestones, but also regulator
Parallelism Challenges When Using Commercial Kits for Biomarker Quantitation
Top 5 Scientific Resources in CNS Clinical Trials
Scientific Resources in CNS Clinical Trials
Altasciences has an extensive understanding of psychiatric and neurologic disorders, stemming from our decades of conducting complex studies in various therapeutic indications impacting the central nervous system.
Here are some of our most insightful scientific resources in the area of CNS drug development:
- The Altascientist: Central Nervous System
Early phase development of CNS-acting drugs is a complex, challenging undertaking. In this article, we provide a detailed overview of the multiple facets you need to consider during the planning and conduct of your CNS-active drug development. Learn More
- The Altascientist: CNS, Psychedelics and Other Schedule I Drugs
In this scientific journal, we uncover the regulatory environment and challenges, the required preclinical and clinical studies specific to Schedule I or Class I (CI) drugs, and the manufacturing considerations for CNS-active drugs. Learn More
- The Altascientist: Studying the Effects of Drugs on Driving
Driving simulation studies are required by the FDA when preclinical and early clinical studies show that a drug may cause somnolence or impair cognition. Discover the challenges of driving simulation clinical testing. Learn More
- Webinar: Navigating the Abuse Potential Evaluation of CNS-active Drugs for EU and U.S. Submissions
In this on-demand webinar, we discuss the key considerations for delivering an integrated preclinical and clinical abuse potential drug development evaluation that meets EMA and FDA regulatory requirements. Watch Now
- Webinar: Inside the Pharmacodynamic Toolbox: How Questionnaires, Models, and Tests of Cognition Can Accelerate the Development of CNS-active Drugs
This session explores the flexible selection of pharmacodynamic measures to enhance the pharmacology, safety, and efficacy. Watch Now
Speak with an expert today to learn more about our CNS solution.
Have five more minutes? Check out these webpages:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.
Integrated Approach to Biomarkers
Biomarkers Inform the Drug Development Process for Large and Small Molecule Drugs
Altasciences can extract meaningful data from measuring various intracellular, membrane-bound, and secreted circulating biomarkers to inform the development process.
We will help guide you towards a robust and fit-for-purpose biomarker solution involving veteran scientists, toxicologists and clinical pharmacologists to develop a comprehensive preclinical to clinical plan to maximize the translation of results from one phase to the next.
Expertise working with:
|
Experience with the following studies:
|
You may also be interested in the following:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Top 5 Ways Liquid-Filled Capsules Accelerate Your Drug Development
Advantage of Liquid-Filled Capsules in Drug Development
Choosing the right dosage form for your API can be the key to accelerating your drug development timeline.
Liquid-filled, hard-shell capsules offer countless benefits over tablets and other solid oral dosage forms, in all phases of drug development ― especially for highly potent or challenging APIs.
View the infographic to learn more!
Have questions? Speak with one of our experts.
You may also be interested in:
- Webpage: Full Range of Manufacturing and Analytical Services
- Video: Quick Chat on Liquid-Filled Capsules with Ben Reed, General Manager, CDMO
- Webinar: The Development of Nanosuspension Formulations for Poorly Soluble Drugs
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Altasciences Receives CRO Leadership Award in Five Categories
Laval, Quebec, May 30, 2022 – Altasciences announced today that it has been awarded a 2022 CRO Leadership Award in five categories, marking the seventh year the CRO/CDMO has been deemed a top performer by Clinical Leader and Life Science Leader.
Each year, Clinical Leader and Life Science Leader team up with ISR Reports to determine award recipients by assessing 50 CROs on more than 20 performance metrics in ISR’s annual Quality Benchmarking survey. This year, Altasciences received awards in the following categories: Capabilities, Compatibility, Expertise, Quality, and Reliability.
“Selecting the right CRO can make or break your project,” says Ed Miseta, Chief Editor for Clinical Leader. “It can lead to a successful regulatory submission and approval or cost you a lot of time and effort on a failed study. That makes CRO selection a stressful decision for any clinical operations manager. We believe our CRO Leadership Awards will help managers with their search process and hopefully help to connect them with the right contract partner. These award winners have proven themselves to be the top service providers in each category. I congratulate all of them for work ethic they exhibit in consistently meeting the needs of their drug development clients.”
Altasciences recognizes the importance of consistently exceeding the standards for excellence set by others in the industry, as well as their own. For more than 10 years, Altasciences has been transforming the traditional outsourcing paradigm, building a one-stop outsourcing solution that simplifies and accelerates the early phase drug development process for our partners. To that end, Altasciences is proud to have exceeded the expectations of small to large pharmaceutical companies, and will use the awards as further motivation to support educated, faster, integrated, and more complete early drug development decisions for their partners.
“To be recognized by the industry is not only an honor but a testament to the expertise of our people and the utmost care they show for both our partners and for those who seek the therapies we help develop,” says Chris Perkin, CEO at Altasciences. “To be acknowledged is a point of pride for our company, yes — but more importantly, it serves as a reminder that the more we build on our Capabilities, Compatibility, Expertise, Quality, and Reliability, the more our solutions can help our clients transform lives around the world.”
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
CONTACT:
Julie-Ann Cabana
Altasciences
514 601-9763
jcabana@altasciences.com
Moving in Unison with YOUR Projects in Mind
Three Strategically Located Preclinical Sites
Our three preclinical sites work in unison with our clinical, bioanalytical and manufacturing sites to offer an integrated drug development solution from lead candidate selection to clinical proof of concept. We offer a full range of in vivo non-GLP and GLP preclinical studies in both rodent and non-rodent species to thoroughly assess the safety of your molecules.
Our purpose-built:
- 550,000 sq.-ft.
- 260 custom-designed animal rooms, including North-American and European housing
- Capacity to house 3,320 NHPs, 965 canines, 920 swine, 27,320 rodents, 2,480 rabbits
- Barrier facilities for small animals
- Archive facility and services on site
- Laboratory services on site
You may also be interested in the following:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.
Real-World Insights from Biopharma Exec Survey — Selecting the Right CRO
One-Stop Solution for Meeting Your Needs in Outsourcing Drug Development
Altasciences recently conducted a survey to understand the challenges biopharmaceutical companies face when outsourcing their early phase drug development programs. Over 143 executives shared the important factors that guide them in the selection of a CRO partner.
Their candid testimonials are shared in this playbook, including:
- The significant challenges encountered when conducting preclinical and Phase I studies
- The unique difficulties of transitioning from preclinical to first-in-human studies
- The specific capabilities and expertise executives look for in their CRO partners
- The novel drug development solution approach for addressing the challenges encountered
Download your copy today.
Let us help! Speak with our experts today.
You may also be interested in the following:
Webpages:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.